Cardiovascular Complications in Children with HIV Infection

被引：15

作者：

Sims A. ^{[1
]}

Hadigan C. ^{[2
]}

机构：

[1] Children's National Medical Center, West Wing, Floor 3, Washington, DC 20010

[2] Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, NIH, 10 Center Drive, Bldg 10

来源：

Current HIV/AIDS Reports | 2011年 / 8卷 / 3期

关键词：

AIDS; Antiretroviral; Atherosclerosis; Biomarkers; Cardiovascular complications in children with HIV infection; Cardiovascular disease; HIV; Inflammation; Metabolic; Lipodystrophy; Pediatric; Strain;

D O I：

10.1007/s11904-011-0081-9

中图分类号：

学科分类号：

摘要：

Before effective antiretroviral treatment was introduced in children with HIV, cardiovascular complications were a major cause of morbidity and mortality. Now that antiretroviral treatment is the standard of care in this population, there has been a shift from fulminant cardiovascular complications to recognition of cardiovascular issues related to HIV as a chronic disease state and its treatment. This review explores the recent advances in understanding the roles of atherosclerosis, inflammation, biomarkers, and metabolic abnormalities in cardiac function and cardiovascular disease risk in children with HIV. The true risk and prevalence of cardiovascular outcomes in HIV-infected children and adolescents has yet to be realized. Recently, however, investigators are exploring new cardiovascular health challenges that face children living with HIV, and developing strategies to lower the cardiovascular disease risk for these children. © Springer Science+Business Media, LLC 2011.

引用

页码：209 / 214

页数：5

共 39 条

[1]

Luginbuhl L.M., Orav E.J., McIntosh K., Lipshultz S.E., Cardiac morbidity and related mortality in children with HIV infection, Journal of the American Medical Association, 269, 22, pp. 2869-2875, (1993)

[2]

Miller T.L., Orav E.J., Lipshultz S.E., Et al., Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1, J Pediatr, 153, pp. 491-497, (2008)

[3]

Werner M.L., Pone M.V., Fonseca V.M., Chaves C.R., Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy, J Pediatr, 86, pp. 27-32, (2010)

[4]

Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A.D'A., El-Sadr W., Thiebaut R., De Wit S., Kirk O., Fontas E., Law M.G., Phillips A., Lundgren J.D., Class of antiretroviral drugs and the risk of myocardial infarction, New England Journal of Medicine, 356, 17, pp. 1723-1735, (2007)

[5]

Phillips A.N., Carr A., Neuhaus J., Visnegarwala F., Prineas R., Burman W.J., Williams I., Drummond F., Duprez D., Belloso W.H., Goebel F.-D., Grund B., Hatzakis A., Vera J., Lundgren J.D., Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: Exploratory analyses from the SMART trial, Antiviral Therapy, 13, 2, pp. 177-187, (2008)

[6]

Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R., Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome, J Clin Endocrinol Metab, 74, pp. 1045-1052, (1992)

[7]

Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., D'Arminio Monforte A., Pradier C., Morfeldt L., Mateu S., Law M., El-Sadr W., De Wit S., Sabin C.A., Phillips A.N., Lundgren J.D., Cardiovascular disease risk factors in HIV patients - Association with antiretroviral therapy. Results from the DAD study, AIDS, 17, 8, pp. 1179-1193, (2003)

[8]

Lundgren J.D., Babiker A., El-Sadr W., Emery S., Grund B., Neaton J.D., Neuhaus J., Phillips A.N., Inferior clinical outcome of the CD4 <sup>+</sup> cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4 <sup>+</sup> cell counts and HIV RNA levels during follow-up, Journal of Infectious Diseases, 197, 8, pp. 1145-1155, (2008)

[9]

Lo J., Abbara S., Shturman L., Et al., Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men, AIDS, 24, pp. 243-253, (2009)

[10]

Emery S., Neuhaus J.A., Phillips A.N., Babiker A., Cohen C.J., Gatell J.M., Girard P.-M., Grund B., Law M., Losso M.H., Palfreeman A., Wood R., Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study, Journal of Infectious Diseases, 197, 8, pp. 1133-1144, (2008)

← 1 2 3 4 →